Designing antibodies with atomic precision
Expanding the universe of druggable targets by developing integrated AI and experimental technologies
AI is the most rapidly evolving and impactful technology humanity has possessed. We can use it to design drugs and their interactions with atomic precision.
Although this represents a step change for drug design, the full complexity of human biology surpasses our understanding and AI's training scope. So, it's critical that we also develop methods to empirically measure human-relevant drug properties at scale.
At Nabla we believe it's the close integration of AI-guided design and wet-lab driven measurement that will enable the design of drugs with superior manufacturability, safety, and efficacy for diseases that elude us today.
Generative drug design meets massively parallel experimentation
Founded by pioneers of protein language modeling, Nabla develops generative models, multiplexed screens, and protein characterization technologies and applies them to design antibodies against the most challenging disease targets, from GPCRs to ion channels.
Partnering with the world's leading pharmaceutical companies
To maximize the impact of our platform, we are partnering with leading pharmaceutical companies to design drugs and bring them to patients.
We're a focused, creative team with high scientific standards
